Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p7
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 7/16)
Character Range: 136511–139419

units or less and not more than 10 days' supply; and

          (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
 (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

          (i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

          (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.
FLUORIDES for human use:

       (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

       (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child‑resistant closure:

          (i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child‑resistant closure and compliant with the requirements of required advisory statements for medicine labels; or

          (ii) for non‑therapeutic use when labelled with warnings to the following effect:

             (A) Do not swallow; and

             (B) Do not use [this product/insert name of product] in children 6 years of age or less;

           except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child‑resistant closure and labelled with warnings to the following effect:

             (C) Do not swallow; and

             (D) Do not use [this product/insert name of product] in children 6 years of age or less;

     except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in preparations for topical oral use when:
 (a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when:

          (i) in a primary pack containing not more than 16 dosage units; and

          (ii) labelled only for the treatment of adults and children over 12 years; or
 (b) in undivided preparations containing either:

          (i) 0.25% or less of flurbiprofen per dose; or

          (ii) 10 mg or less of flurbiprofen per dose;
 except when:

          (iii) in a primary pack containing not more than 15 mL; and

          (iv) labelled only for the treatment of adults 18 years and over.
FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use